Search hospitals

>

California

>

Arroyo Grande

PCR Oncology

Claim this profile

Arroyo Grande, California 93420

Global Leader in Lung Cancer

Global Leader in Breast Cancer

Conducts research for Breast cancer

Conducts research for Cancer

Conducts research for Non-Small Cell Lung Cancer

182 reported clinical trials

3 medical researchers

Photo of PCR Oncology in Arroyo GrandePhoto of PCR Oncology in Arroyo Grande

Summary

PCR Oncology is a medical facility located in Arroyo Grande, California. This center is recognized for care of Lung Cancer, Breast Cancer, Breast cancer, Cancer, Non-Small Cell Lung Cancer and other specialties. PCR Oncology is involved with conducting 182 clinical trials across 315 conditions. There are 3 research doctors associated with this hospital, such as John A. Ellerton, Alan K. Ikeda, and David Palchak, MD.

Area of expertise

1

Lung Cancer

Global Leader

PCR Oncology has run 43 trials for Lung Cancer. Some of their research focus areas include:

Stage IV
Stage II
Stage I
2

Breast Cancer

Global Leader

PCR Oncology has run 38 trials for Breast Cancer. Some of their research focus areas include:

HER2 negative
ER positive
Stage IV

Top PIs

Clinical Trials running at PCR Oncology

Breast Cancer

Bladder Cancer

Lung Cancer

Ovarian Cancer

Breast cancer

Kidney Cancer

Esophageal cancer

Cancer

Prostate Cancer

Bladder Carcinoma

Image of trial facility.

Chemotherapy + Hormone Therapy

for Breast Cancer

This trial is testing if adding additional cancer-fighting drugs to treatments that stop certain body functions is better than just using the treatments that stop those functions alone. It targets younger women with early-stage breast cancer who have a higher risk of dying from the disease. The treatment works by stopping certain body functions and using drugs to kill cancer cells.

Recruiting

2 awards

Phase 3

19 criteria

Image of trial facility.

Radiation and HER2-Targeted Therapy

for Breast Cancer

This Phase III trial compares the recurrence-free interval (RFI) among patients with early-stage, low risk HER2+ breast cancer who undergo breast conserving surgery and receive HER2-directed therapy, and are randomized to not receive adjuvant breast radiotherapy versus those who are randomized to receive adjuvant radiotherapy per the standard of care.

Recruiting

2 awards

Phase 3

15 criteria

Image of trial facility.

Shorter Chemo-Immunotherapy Without Anthracyclines

for Breast Cancer

This phase III trial compares the effects of shorter chemotherapy (chemo)-immunotherapy without anthracyclines to usual chemo-immunotherapy for the treatment of early-stage triple negative breast cancer. Paclitaxel is in a class of medications called anti-microtubule agents. It stops cancer cells from growing and dividing and may kill them. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of cancer cells. Cyclophosphamide is in a class of medications called alkylating agents. It works by damaging the cell's deoxyribonucleic acid (DNA) and may kill cancer cells. It may also lower the body's immune response. Docetaxel is in a class of medications called taxanes. It stops cancer cells from growing and dividing and may kill them. Doxorubicin is an anthracycline chemotherapy drug that damages DNA and may kill cancer cells. Pembrolizumab may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Shorter treatment without anthracycline chemotherapy may work the same as the usual anthracycline chemotherapy treatment for early-stage triple negative breast cancer.

Recruiting

2 awards

Phase 3

47 criteria

Similar Hospitals nearby

Frequently asked questions

What kind of research happens at PCR Oncology?